# XmAb819-01: HCP commentary report

> 29 verified statements (18 from clinicians verified by NPI or staff page) from 15 commentary sources · 4 findings · updated Oct 29, 2026

## Report

- Trial: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
- NCT ID: NCT05433142
- Registry: https://clinicaltrials.gov/study/NCT05433142
- Sponsor: Xencor, Inc.
- Phase: Phase 1
- Status: Recruiting
- Version: v1.0.0, edition 1
- Accepted: 2026-10-29
- Last checked: 2026-10-29
- Release hash: 207a5fb68da2dad48016f08cd4337267502203f25207dc2de00d512b46f86c10

## Counts

- HCP commentary sources screened: 24
- Sources cited by verified statements: 15
- Verified statements: 29
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 18
- Findings: 4
- People found in screened sources: 10
- Voices cited: 10
- Cited voices identity-verified: 9
- Organisational or shared accounts (not counted as people): 3

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

XmAb819-01 examines the safety and tolerability of XmAb819 in relapsed or refractory clear-cell kidney cancer. One X poster supports continued development; a therapeutic role remains an open question in an X post. A differentiated mechanism attracts interest from an X poster, while an X post highlights a toxicity-management learning need. Confirmation of the high-dose signal remains questioned in an X post. The sources reviewed for this edition place the trial’s main results at ESMO 2026.

## Open Medical Affairs question

What durability, safety burden and confirmatory evidence would make this mechanism clinically meaningful after existing therapies?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. A differentiated mechanism attracts interest, but becoming a therapeutic pillar remains a question
- F2. Dose-dependent activity supports development, but the high-dose estimate is not confirmation
- F3. Manageable toxicity descriptions coexist with substantial adverse-event burden and a management learning need
- F4. Regulatory ambition is a reported prospect, not an achieved development milestone

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 9 | 6 | 6 | 6 | none recorded | 2 |
| F2 | 11 | 8 | 8 | 8 | recorded | 3 |
| F3 | 10 | 10 | 10 | 10 | recorded | 3 |
| F4 | 2 | 2 | 2 | 2 | none recorded | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 7 | 1 | 0 | 0 | 1 | 10 | 0 | 6 posts and articles | yes |
| F2 | 4 | 1 | 0 | 0 | 6 | 11 | 0 | 8 posts and articles | yes |
| F3 | 3 | 1 | 0 | 0 | 6 | 10 | 0 | 10 posts and articles | yes |
| F4 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles | yes |

### Trial dimensions

- Primary endpoint: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819): F3 (1 shared claims)
- Primary endpoint: Incidence of dose limiting toxicities (DLTs): no finding draws on it directly
- Secondary endpoints: F1 (1 shared claims), F2 (7 shared claims), F3 (4 shared claims)
- Population and setting: F1 (3 shared claims), F2 (3 shared claims), F4 (1 shared claims)
- The comparison: F2 (2 shared claims), F3 (3 shared claims)
- Safety and tolerability: F1 (1 shared claims), F2 (2 shared claims), F3 (10 shared claims)
- Design and conduct: F2 (3 shared claims), F3 (1 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. Dose-dependent activity supports development, but the high-dose estimate is not confirmation

An X post addresses the question of what evidence would establish confirmation of the high-dose activity signal.

The poster’s individual identity and clinical role are not confirmed in the sources reviewed for this edition.

Source: X thread, 2026-10-26.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 5 sections | Paid |
| Verified statements with short source quotes and links | 29 | Paid |
| Trial aspects mapped | 10 | Free |
| Sources with links | 15 | Counts free |
| Speaker attribution for cited voices | 10 | Paid |

## Trial aspects

9 discussed · 1 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819) | discussed | 1 | 1 |
| Primary endpoint: Incidence of dose limiting toxicities (DLTs) | no commentary found | 0 | 0 |
| Secondary endpoints | discussed | 9 | 8 |
| Population and setting | discussed | 6 | 4 |
| The comparison | discussed | 4 | 3 |
| Safety and tolerability | discussed | 10 | 10 |
| Design and conduct | discussed | 4 | 4 |
| High-dose evidence and small-sample uncertainty | discussed | 9 | 7 |
| Mechanistic differentiation and the proposed late-line therapeutic role | discussed | 10 | 7 |
| Prospective development and regulatory expectations | discussed | 4 | 4 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 23 | 14 |
| Bluesky threads | 1 | 1 |

- Screened window: 2025-07-16 to 2026-10-27
- Cited window: 2025-11-20 to 2026-10-27
- Retrieved: 2026-10-29

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma
- Registry: NCT05433142 (https://clinicaltrials.gov/study/NCT05433142)
- Study IDs: XmAb819-01
- Sponsor: Xencor, Inc.
- Design: Phase 1 · interventional, na, sequential, phase1
- Status: Recruiting
- Enrollment: 307 (estimated)
- Start: 2022-06-13 (actual)
- Primary completion: 2027-02 (estimated)
- Primary endpoint: Incidence of treatment-emergent adverse events (safety and tolerability of XmAb819) (28 days)
- Primary endpoint: Incidence of dose limiting toxicities (DLTs) (28 days)
- Intervention: XmAb819 (biological)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on treatment activity after prior therapy and continued treatment among responders in heavily pretreated clear cell renal cell carcinoma.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits apply, so some matching discussion may be missing.
- The sources reviewed for this edition are not a representative sample of HCP opinion. Organizational reports, analyst assessments and reposts must not be counted as independent clinician endorsements.
- Some discussions were only partly assessed, and 52 additional sources without an explicit trial-name mention were not read. Relevant discussion using unnamed references or different transcription variants may be missing.
- Several posts discuss XmAb819 or its phase 1 ccRCC setting without identifying NCT05433142. Their observations remain attributed contextual reports rather than independently identifier-confirmed results.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No full protocol, results publication for NCT05433142 or XmAb819 regulatory label was available in the sources reviewed. The reported efficacy, toxicity and development assertions cannot be reconciled against those documents here.
- Different cohort scopes, adverse-event categories and cutoff descriptions prevent combining the reported figures into one efficacy or safety estimate. Treatment persistence does not establish mature duration of response.
- The a speaker post is dated November 2025, whereas the other cited commentary is dated October 2026. Post dates do not establish readout dates, longitudinal changes of view or direct disagreement.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-10-29: current edition

Last checked for new commentary 2026-10-29. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (29 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (9 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/xmab819-01-nct05433142
- Agents: POST https://www.erudio.com/api/orders with {"report": "xmab819-01-nct05433142", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=xmab819-01-05433142

## Cite

Erudio Health. XmAb819-01 (NCT05433142): HCP commentary report. Edition 1, v1.0.0. Accepted Oct 29, 2026. https://www.erudio.com/reports/xmab819-01-nct05433142

## Machine access

- JSON: https://www.erudio.com/reports/xmab819-01-nct05433142.json
- Markdown: https://www.erudio.com/reports/xmab819-01-nct05433142.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "xmab819-01-05433142"}`